info@seagull-health.com

SeagullHealth

语言:

Homepage

Drugs

Belzutifan(Welireg)

Names

Welireg,Belzutifan,贝组替凡

Indicatons

Adult patients with renal cell carcinoma, central nervous system hemangioblastoma, or pancreatic neuroendocrine tumors.

Price:

Manufacturer:

MSD

Dosage form:

TABLET

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Welireg(Belzutifan) Instructions:Uses,Dosage, Side Effects

WELIREG, with the active pharmaceutical ingredient belzutifan, is an orally administered medication available as 40 mg film-coated tablets. Chemically, belzutifan is 3-[[(1S,2S,3R)-2,3-Difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl]oxy]-5-fluorobenzonitrile. It is designed for therapeutic use in adult patients with specific oncological conditions, including tumors associated with von Hippel-Lindau disease and certain types of advanced kidney cancer.

The therapeutic effect of belzutifan is derived from its activity as an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2αα). HIF-2αα is a key transcription factor that plays a significant role in the body's oxygen-sensing mechanisms by modulating genes involved in adaptation to hypoxic (low oxygen) conditions. By targeting and inhibiting HIF-2αα, WELIREG interferes with cellular pathways that contribute to the growth and progression of certain cancers.

Generic name

Belzutifan(Welireg)

English name

Belzutifan

Alternative Names

Welireg,Belzutifan,贝组替凡

Drug prices

Indications

1. Von Hippel-Lindau (VHL) disease: For the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.

2. Advanced Renal Cell Carcinoma (RCC): For the treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).

Therapeutic Target

Hypoxia-inducible factor 2 alpha (HIF-2 α α).

Active Ingredients

Belzutifan

Dosage Form

TABLET

Specifications

40mg*90 tablets/bottle

Dosage and Administration

The recommended dosage of WELIREG is 120 mg administered orally once daily until disease progression or unacceptable toxicity. It should be taken at the same time each day and may be taken with or without food.

Related Columns

Recommended articles

What Are the Purchase Channels for Belzutifan (Welireg)?

Belzutifan (Welireg) is a prescription medication indicated for the treatment of von Hippel-Lindau (VHL)-associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancr...

What are the Indications for Belzutifan (Welireg)?

Belzutifan (Welireg) is an oral hypoxia-inducible factor inhibitor (HIF-2α inhibitor) that received its first approval for marketing in the United States in 2021.What are the Indications for Belzutifa...

Dosage and Administration of Belzutifan (Welireg)

Belzutifan (Welireg) is a hypoxia-inducible factor-2α (HIF-2α) inhibitor that received its first approval in the United States in 2021. It is primarily indicated for the treatment of adult patients wi...

Is there anything to pay attention to when taking Belzutifan(Welireg)?

Befativan(WELIREG) is an innovative drug that offers a new option for the treatment of von Hippel-Lindau (VHL) syndrome. While understanding the drug use and adverse reactions of its special populatio...

The efficacy of Belzutifan

Belzutifan(Welireg) is a drug specifically designed to target tumors associated with von Hippel-Lindau (VHL) syndrome. By targeting HIF-2α, it is able to effectively inhibit the abnormal proliferation...

What are the adverse effects of Belzutifan(WELIREG)?

Although Belzutifan(WELIREG) is an innovative drug for the treatment of von Hippel-Lindau (VHL) syndrome, although it brings new hope for treatment to patients, the adverse reactions that may be cause...

Departments